I'm just a lot more wary of ann's that tout something without actual clinical trails/results. Doesn't matter what the company or sector, until something concrete is announced I always remain skeptical. We know nothing about these 12 people, demographical background, age, gender, underlying conditions??? Don't get me wrong, it's very promising but that's all it is at the moment.
I have been burnt before by pre-empting or reading more into an ann than what's there. I know you have too re: CLI.
I hope as much as you that this is successful but until we have more information let's not get too ahead of ourselves.
Ann: 83% Survival in COVID-19 ARDS Patients with Remestemcel-L, page-437
-
- There are more pages in this discussion • 411 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.38 |
Change
-0.080(5.50%) |
Mkt cap ! $1.587B | |||
| Open | High | Low | Value | Volume |
| $1.43 | $1.43 | $1.37 | $4.023M | 2.884M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 15 | 44575 | $1.37 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.38 | 89904 | 15 |
View Market Depth
| Last trade - 14.31pm 16/10/2024 (20 minute delay) ? |
| MSB (ASX) Chart |